Name (Synonyms) | Correlation | |
---|---|---|
D009202 | Cardiomyopathies NIH | 0.58 |
D002318 | Cardiovascular Diseases NIH | 0.21 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0001638 | Cardiomyopathy HPO | 0.58 |
HP:0001626 | Abnormality of the cardiovascular system HPO | 0.21 |
There is one clinical trial.
COVID-19 is associated with complications including ARDS and myocardial injury, which informs prognosis and patient outcome. The laboratory plans to perform immunophenotyping of peripheral T-cells in patients with COVID-19 and complications (ARDS, ITU admission, myocardial injury) and map this against clinical patient outcomes. The aim is to determine if there is a specific T-cell immunophenotype associated with COVID-19 and/or complications, which can be used to inform prognosis and potential therapies.
Description: T-cell immunophenotype
Measure: T-cell immunophenotype Time: 12 months from enrollmentDescription: death, survival to discharge
Measure: Mortality Time: 12 months from enrolmentDescription: Admission to the intensive care
Measure: ITU admission Time: 12 months from enrolmentDescription: Defined by troponin rise to >99th centile
Measure: Myocardial injury Time: 12 months from enrolment